Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 471-475

  Masana, Luís ^a   Ibarretxe, Daiana ^a   Heras, Mercedes ^a   Cabré, Anna ^a   Ferré, Raimon ^a   Merino, Jordi ^a   Plana, Núria ^a   Girona, Josefa ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Cardiovascular risk; LDL; Lipid lowering; Non HDL cholesterol

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; RETROSPECTIVE STUDIES; TRIGLYCERIDES; ULTRACENTRIFUGATION;

EID: 84872402984     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.12.001     Document Type: Article

References (35)

1. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
2. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
3. Havel R.J. Triglyceride-rich lipoproteins and plasma lipid transport. Arterioscler Thromb Vasc Biol 2010, 30:9-19.
4. Le N.A., Walter M.F. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 2007, 9:110-115.
5. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
6. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81:7B-12B.
7. Tirosh A., Rudich A., Shochat T., et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007, 147:377-385.
8. Sprecher D.L. Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit. Curr Cardiol Rep 2001, 3:424-432.
9. Talayero B.G., Sacks F.M. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011, 13:544-552.
10. Bittner V. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy. Prev Cardiol 2004, 7:122-126. quiz 29-30.
11. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. J Am Med Assoc 2012, 307:1302-1309.
12. Ganda OP, Jumes CG, Abrahamson MJ, et al. Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. Diabetes Res Clin Pract.
13. Sniderman A., Williams K., de Graaf J. Non-HDL C equals apolipoprotein B: except when it does not!. Curr Opin Lipidol 2010, 21:518-524.
14. van Deventer H.E., Miller W.G., Myers G.L., et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem 2011, 57:490-501.
15. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
16. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26:16-23.
17. Miller M., Ginsberg H.N., Schaefer E.J. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008, 101:1003-1008.
18. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. J Am Med Assoc 2005, 294:326-333.
19. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
20. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
21. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
22. Waters D.D., Brotons C., Chiang C.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
23. Negi S.I., Steinberg L., Polsani V.R., et al. Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. J Clin Lipidol 2012, 6:50-57.
24. Virani S.S., Steinberg L., Murray T., et al. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med 2011, 124:876-880. e2.
25. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Meth Enzymol 1986, 128:155-170.
26. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
27. Tonelli M., Keech A., Shepherd J., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005, 16:3748-3754.
28. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
29. Hussein A.A., Uno K., Wolski K., et al. Intensive multi-target lipid lowering and progression of coronary atherosclerosis. Circulation 2010, 122:A13108. Abstract.
30. Bayturan O., Kapadia S., Nicholls S.J., et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 2010, 55:2736-2742.
31. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
32. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
33. Kizer J.R., Madias C., Wilner B., et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol 2010, 105:1289-1296.
34. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
35. The ORIGIN Trial Investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318.